|
|
|
|
|
|
|
|
|
sponsored by
|
|
|
|
Moving beyond innovation for ADC success
|
| Innovation alone isn’t enough. Antibody-drug conjugates require alignment across dosing, biomarkers and global trial strategy to move programs forward with greater speed and confidence. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharma execs talk in glowing terms about how AI will transform their businesses, but the researchers they need to lead those transitions don’t seem interested in what they’re offering. Endpoints’ Andy Dunn took a trip to Brazil to learn more. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
The 2026 ICLR conference in Rio de Janeiro (Andrew Dunn for Endpoints News) |
|
|
|
by Andrew Dunn
|
RIO DE JANEIRO — Mazdak Abulnaga should be the poster child for the type of employee pharma companies want to hire this year. Abulnaga, a... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Capricor Therapeutics said Thursday it has filed a lawsuit against Nippon Shinyaku over a distribution and commercialization agreement for deramiocel, a cell therapy candidate for... | |
|
|
|
|
|
 |
|
|
|
by ENDPOINTS |
🗓️ FDA delays subcutaneous Leqembi decision: Originally slated for later this month, the decision date now falls on August 24, Biogen and Eisai said... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. With its IPO now priced, Odyssey... | |
|
|
|
 |
|
|
|
by Alex Hoffman, Kyle LaHucik
|
|
|
|
